Geninus Receives Interest from Major Japanese Pharmaceutical Company... Accelerates Export of AI Drug Discovery Platform

Geninus is accelerating the expansion of its AI-based drug discovery platform business, leveraging its collaboration with a major Japanese pharmaceutical company.

Geninus, a genomics and AI drug discovery platform company led by CEO Ung Yang Park, announced on March 24 that its Japanese subsidiary GxD has signed a project contract based on the "IntelliMed" platform with a leading local pharmaceutical company and has officially begun business operations. This contract marks the first phase of a three-stage collaboration process, and it is significant in that it is highly likely to lead to additional contracts and a long-term partnership in the future.

In this project, GxD will conduct spatial omics and single-cell genomic analysis using clinical samples, and will support the drug development process through AI-based data interpretation. In particular, the company emphasized that the interpretation of analysis results is conducted directly by professionals, which increases the utility of the data.

The industry is paying attention to this contract because it was secured in the Japanese pharmaceutical market, which is known for its stringent quality standards and high entry barriers. Analysts view this as evidence that Geninus' technological capabilities are competitive at a global level.

Geninus plans to use this contract as a stepping stone to establish a reference in Japan and pursue additional contracts, while also actively expanding its drug discovery platform business to target global pharmaceutical companies.

Expectations for performance growth are also rising. The company projected that, based on its business expansion in the Japanese market, its subsidiary GxD's revenue in 2026 will increase by more than 80% compared to the previous year.

A company representative stated, "This achievement is meaningful as it demonstrates our ability to meet the high quality standards and operational requirements of Japanese pharmaceutical companies," and added, "We will accelerate our entry into the global market with Japan as a base and further strengthen our position as an AI drug discovery platform company."

This content was produced with the assistance of AI translation services.